FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113711277> ?p ?o ?g. }

• W3113711277 endingPage "489" @default.
• W3113711277 startingPage "484" @default.
• W3113711277 abstract "ObjectiveThe aim was to compare the safety and effectiveness of rivaroxaban and warfarin as anticoagulants for treating patients with post-thrombotic syndrome (PTS) with chronic iliofemoral venous occlusion undergoing iliofemoral venous stenting.MethodsThis single institution retrospective study analysed patients with PTS with chronic iliofemoral venous occlusion who were prescribed rivaroxaban or warfarin for one year after successfully undergoing iliofemoral venous stenting. The primary safety and efficacy endpoints were bleeding complication rate and primary patency rate at one year. Secondary outcomes included Villalta score, symptom recurrence rate, ulcer healing rate, and clinically driven target lesion revascularisation (CD-TLR) rate during follow up.ResultsFrom January 2016 to December 2017, 154 legs from 154 patients were included in this study (69 in rivaroxaban group and 85 in warfarin group). The groups were well matched for patient demographics, clinical characteristics, and procedural details. There was no significant difference between the rivaroxaban group and warfarin group in bleeding complication rate (10% vs. 16%, p = .23, hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.25 – 1.37) at one year, as well as major bleeding complication rate (0% vs. 2%, p = .20, HR 0.16, 95% CI 0.01 – 2.61) and minor bleeding complication rate (10% vs. 14%, p = .40, HR 0.67, 95% CI 0.27 – 1.66). The primary patency rate was higher in the rivaroxaban group at one year (84% vs. 71%, p = .049, HR 0.50, 95% CI 0.26 – 0.96) and at two years (79% vs. 63%, p = .037, HR 0.52, 95% CI 0.29 – 0.93). At a mean follow up of 24 months (range 1 – 42 months), the rivaroxaban group had a significantly lower post-operative Villalta score (4.87 ± 3.51 vs. 6.88 ± 5.85, p = .010, t = 2.64, 95% CI 0.50 – 3.52), lower rate of symptom recurrence (4% vs. 32%, p < .001), lower CD-TLR rates (3% vs. 13%, p = .039), and higher ulcer healing rate (90% vs. 59%, p = .004) than the warfarin group.ConclusionFor PTS patients with chronic iliofemoral venous occlusion undergoing iliofemoral venous stenting, rivaroxaban probably exhibited similar safety but superior efficacy to warfarin. However, further prospective control studies with large sample size are necessary to confirm the results. The aim was to compare the safety and effectiveness of rivaroxaban and warfarin as anticoagulants for treating patients with post-thrombotic syndrome (PTS) with chronic iliofemoral venous occlusion undergoing iliofemoral venous stenting. This single institution retrospective study analysed patients with PTS with chronic iliofemoral venous occlusion who were prescribed rivaroxaban or warfarin for one year after successfully undergoing iliofemoral venous stenting. The primary safety and efficacy endpoints were bleeding complication rate and primary patency rate at one year. Secondary outcomes included Villalta score, symptom recurrence rate, ulcer healing rate, and clinically driven target lesion revascularisation (CD-TLR) rate during follow up. From January 2016 to December 2017, 154 legs from 154 patients were included in this study (69 in rivaroxaban group and 85 in warfarin group). The groups were well matched for patient demographics, clinical characteristics, and procedural details. There was no significant difference between the rivaroxaban group and warfarin group in bleeding complication rate (10% vs. 16%, p = .23, hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.25 – 1.37) at one year, as well as major bleeding complication rate (0% vs. 2%, p = .20, HR 0.16, 95% CI 0.01 – 2.61) and minor bleeding complication rate (10% vs. 14%, p = .40, HR 0.67, 95% CI 0.27 – 1.66). The primary patency rate was higher in the rivaroxaban group at one year (84% vs. 71%, p = .049, HR 0.50, 95% CI 0.26 – 0.96) and at two years (79% vs. 63%, p = .037, HR 0.52, 95% CI 0.29 – 0.93). At a mean follow up of 24 months (range 1 – 42 months), the rivaroxaban group had a significantly lower post-operative Villalta score (4.87 ± 3.51 vs. 6.88 ± 5.85, p = .010, t = 2.64, 95% CI 0.50 – 3.52), lower rate of symptom recurrence (4% vs. 32%, p < .001), lower CD-TLR rates (3% vs. 13%, p = .039), and higher ulcer healing rate (90% vs. 59%, p = .004) than the warfarin group. For PTS patients with chronic iliofemoral venous occlusion undergoing iliofemoral venous stenting, rivaroxaban probably exhibited similar safety but superior efficacy to warfarin. However, further prospective control studies with large sample size are necessary to confirm the results." @default.
• W3113711277 created "2021-01-05" @default.
• W3113711277 creator A5003757908 @default.
• W3113711277 creator A5021768333 @default.
• W3113711277 creator A5047704593 @default.
• W3113711277 creator A5050803462 @default.
• W3113711277 creator A5065543108 @default.
• W3113711277 creator A5088241540 @default.
• W3113711277 date "2021-03-01" @default.
• W3113711277 modified "2023-10-12" @default.
• W3113711277 title "Comparing Safety and Efficacy of Rivaroxaban with Warfarin for Patients after Successful Stent Placement for Chronic Iliofemoral Occlusion: A Retrospective Single Institution Study" @default.
• W3113711277 cites W1664566016 @default.
• W3113711277 cites W1684164902 @default.
• W3113711277 cites W1937154689 @default.
• W3113711277 cites W1944762875 @default.
• W3113711277 cites W2013710547 @default.
• W3113711277 cites W2068802530 @default.
• W3113711277 cites W2103286082 @default.
• W3113711277 cites W2115787552 @default.
• W3113711277 cites W2140582137 @default.
• W3113711277 cites W2143386240 @default.
• W3113711277 cites W2144939065 @default.
• W3113711277 cites W2152623033 @default.
• W3113711277 cites W2154510694 @default.
• W3113711277 cites W2162499932 @default.
• W3113711277 cites W2191131250 @default.
• W3113711277 cites W2225937646 @default.
• W3113711277 cites W2345766056 @default.
• W3113711277 cites W2515550254 @default.
• W3113711277 cites W2557845780 @default.
• W3113711277 cites W2606733053 @default.
• W3113711277 cites W2651542758 @default.
• W3113711277 cites W2740555851 @default.
• W3113711277 cites W2783289631 @default.
• W3113711277 cites W2788271568 @default.
• W3113711277 cites W2789819411 @default.
• W3113711277 cites W2789982920 @default.
• W3113711277 cites W2898144796 @default.
• W3113711277 cites W3023801130 @default.
• W3113711277 doi "https://doi.org/10.1016/j.ejvs.2020.11.050" @default.
• W3113711277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33388238" @default.
• W3113711277 hasPublicationYear "2021" @default.
• W3113711277 type Work @default.
• W3113711277 sameAs 3113711277 @default.
• W3113711277 citedByCount "11" @default.
• W3113711277 countsByYear W31137112772021 @default.
• W3113711277 countsByYear W31137112772022 @default.
• W3113711277 countsByYear W31137112772023 @default.
• W3113711277 crossrefType "journal-article" @default.
• W3113711277 hasAuthorship W3113711277A5003757908 @default.
• W3113711277 hasAuthorship W3113711277A5021768333 @default.
• W3113711277 hasAuthorship W3113711277A5047704593 @default.
• W3113711277 hasAuthorship W3113711277A5050803462 @default.
• W3113711277 hasAuthorship W3113711277A5065543108 @default.
• W3113711277 hasAuthorship W3113711277A5088241540 @default.
• W3113711277 hasBestOaLocation W31137112771 @default.
• W3113711277 hasConcept C126322002 @default.
• W3113711277 hasConcept C141071460 @default.
• W3113711277 hasConcept C167135981 @default.
• W3113711277 hasConcept C207103383 @default.
• W3113711277 hasConcept C2776301958 @default.
• W3113711277 hasConcept C2778661090 @default.
• W3113711277 hasConcept C2779161974 @default.
• W3113711277 hasConcept C42219234 @default.
• W3113711277 hasConcept C44249647 @default.
• W3113711277 hasConcept C71924100 @default.
• W3113711277 hasConcept C81182388 @default.
• W3113711277 hasConceptScore W3113711277C126322002 @default.
• W3113711277 hasConceptScore W3113711277C141071460 @default.
• W3113711277 hasConceptScore W3113711277C167135981 @default.
• W3113711277 hasConceptScore W3113711277C207103383 @default.
• W3113711277 hasConceptScore W3113711277C2776301958 @default.
• W3113711277 hasConceptScore W3113711277C2778661090 @default.
• W3113711277 hasConceptScore W3113711277C2779161974 @default.
• W3113711277 hasConceptScore W3113711277C42219234 @default.
• W3113711277 hasConceptScore W3113711277C44249647 @default.
• W3113711277 hasConceptScore W3113711277C71924100 @default.
• W3113711277 hasConceptScore W3113711277C81182388 @default.
• W3113711277 hasFunder F4320321001 @default.
• W3113711277 hasFunder F4320321885 @default.
• W3113711277 hasIssue "3" @default.
• W3113711277 hasLocation W31137112771 @default.
• W3113711277 hasOpenAccess W3113711277 @default.
• W3113711277 hasPrimaryLocation W31137112771 @default.
• W3113711277 hasRelatedWork W2082030900 @default.
• W3113711277 hasRelatedWork W2097854437 @default.
• W3113711277 hasRelatedWork W2588230836 @default.
• W3113711277 hasRelatedWork W2606162097 @default.
• W3113711277 hasRelatedWork W2789982920 @default.
• W3113711277 hasRelatedWork W2795447945 @default.
• W3113711277 hasRelatedWork W2981470879 @default.
• W3113711277 hasRelatedWork W3097777688 @default.
• W3113711277 hasRelatedWork W3216449487 @default.
• W3113711277 hasRelatedWork W4223900040 @default.
• W3113711277 hasVolume "61" @default.
• W3113711277 isParatext "false" @default.
• W3113711277 isRetracted "false" @default.
• W3113711277 magId "3113711277" @default.

• next